New hope for Tough-to-Treat depression? early drug trial completes
NCT ID NCT06965569
Summary
This small, early-stage study tested a new drug called ALA-3000 in people whose depression had not improved with at least two standard treatments. The main goal was to check the drug's safety, side effects, and how it moves through the body in 37 participants. Researchers also looked for early signs that it might help ease depression symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT RESISTANT DEPRESSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arch Clinical Trials
St Louis, Missouri, 63141, United States
-
Clinilabs Drug Development Corporation
Eatontown, New Jersey, 07724, United States
-
Neuro-Behavioral Clinical Research, Inc
North Canton, Ohio, 44720, United States
-
Pillar Clinical Research
Little Rock, Arkansas, 72204, United States
Conditions
Explore the condition pages connected to this study.